ClinicalTrials.gg
RecruitingNCT07424547Updated Apr 7, 2026

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of SYS6043 in Cancer, Solid Tumor Cancer and Advanced Metastatic Cancer, sponsored by Conjupro Biotherapeutics, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Conjupro Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
386
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works.

Participants will:

  • Provide written informed consent
  • Undergo screening tests to ensure they are eligible for study treatment
  • Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment.
  • Have safety follow-up (SFU), and long-term follow-up.
  • Be followed until progression.
Read the detailed description

This is a multicenter, open-label, Phase I study of dose escalation, PK expansion, and cohort expansion, aiming to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of SYS6043 (a B7-H3-targeted antibody-drug conjugate) in patients with advanced/metastatic solid tumors. It includes three parts, namely dose escalation, PK expansion, and cohort expansion.

Phase Ia dose escalation is the first part (Part 1) of this study. The dose escalation is carried out using BOIN design, to evaluate the MTD/maximum administered dose (MAD) and the RP2D.

Phase Ia PK expansion (Part 2) will be conducted at 2-3 dose levels deemed acceptable (≤MTD) in terms of safety/tolerability as assessed by the SMC, to further evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of SYS6043.

Phase Ib cohort expansion (Part 3) will further evaluate the safety and efficacy of SYS6043 at the selected RP2D dose (1-2 dose levels).

A safety monitoring committee (SMC) will be established for this study. The SMC will continuously review safety during the study period and make decisions on adjustments to dose escalation, addition of new dose groups, recommended doses, and recommended exploratory cohorts. For details, please refer to the SMC Charter.

02

Conditions studied

  • Cancer
  • Solid Tumor Cancer
  • Advanced Metastatic Cancer
  • Prostate
  • Small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer

Keywords

  • ovarian cancer
  • breast cancer
  • small cell lung cancer
  • prostate cancer
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 386 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Conjupro Biotherapeutics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Major:

  • Aged ≥18 years old (on the date of signing the ICF).
  • Advanced/unresectable or solid tumors confirmed by histology or cytology, disease recurrence or progression during or after systemic standard of care, and should be intolerant of or have no available standard of care therapy.
  • Have at least one , according to the (RECIST V1.1). Participants with metastatic castration-resistant prostate cancer (mCRPC) who have only metastases to bone will be evaluated through discussion with the sponsor's medical monitor, before determining whether they can be enrolled.
  • Expected of ≥ 3 months.
  • performance status of 0-1 and no worsening of the score within 28 days prior to enrollment.
  • ≥ 50% as shown by ECHO or MUGA within 28 days prior to enrollment.

Exclusion criteria

Exclusion Criteria:

Major:

  • Prior B7-H3 targeted therapy.
  • Previously received drug therapy with topoisomerase inhibitor antibody-drug conjugate (e.g., trastuzumab deruxtecan).
  • Symptomatic congestive heart failure (CHF) ( [NYHA] Class II-IV) or a history of severe arrhythmia requiring treatment.
  • History of myocardial infarction or unstable angina within 6 months prior to enrollment.
  • Based on the results of three 12-lead (ECG) examinations, the mean (QTcF) corrected by the Fridericia formula for both males and females is prolonged to >470 ms.
  • Unable or unwilling to discontinue concomitant medications known to prolong the QT interval.
  • History of interstitial lung disease (e.g., ILD/non-infectious pneumonia requiring treatment in the past), or currently have interstitial lung disease, or are suspected to have such diseases through imaging examinations during screening.
  • History of underlying lung disorders, including but not limited to pulmonary embolism within 3 months prior to the start of study treatment, severe asthma, severe , restrictive pulmonary disease, and other lung injuries or requiring supplemental oxygen.
  • Any diseases, connective tissue disorders, or inflammatory diseases involving the lungs recorded or suspected during screening (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.).
  • Presence of uncontrolled infection requiring intravenous injection of antibiotics, antiviral drugs, or antifungal drugs.
  • Active and clinically significant bacterial, fungal, viral infection, or infection at screening (HCV antibodies test positive and HCV-RNA levels higher than the lower limit of quantification or 1000 copies/mL (whichever is lower); antibody positive or syphilis antibody positive (with confirmation)..
  • positive and HBV-DNA above the lower limit of quantification or 1,000 copies/mL (500 IU/mL) (whichever is lower). Liver tumor: For participants with liver and HBV infection, HBV DNA must be \<2000 IU/mL before the first dose. Participants who are HBsAg-positive and/or HBV DNA-positive should receive at least 2 weeks of anti-Hepatitis B virus treatment prior to the first dose and be willing to continue treatment during the study.
  • Lactating women (women who are willing to temporarily discontinue breastfeeding will also be excluded), or women confirmed to be pregnant by pregnancy test within 7 days prior to enrollment.
  • Presence of spinal cord compression or clinically active , and/or meningeal metastases, defined as untreated, symptomatic, or requiring corticosteroids or anticonvulsants.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
386 participants (estimated)

Study arms

  • Experimental
    Phase Ia dose escalation is the first part (Part 1) of this study.

    The dose escalation is carried out using BOIN design, to evaluate the MTD/maximum administered dose (MAD) and the RP2D (Recommended phase II dose).

    Drug: SYS6043

  • Experimental
    Phase Ia PK expansion (Part 2).

    Phase Ia PK expansion (Part 2) will be conducted at 2-3 dose levels deemed acceptable (≤MTD) in terms of safety/tolerability as assessed by the SMC, to further evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of SYS6043.

    Drug: SYS6043

  • Experimental
    Phase Ib cohort expansion (Part 3).

    Phase Ib cohort expansion (Part 3) will further evaluate the safety and efficacy of SYS6043 at the selected RP2D dose (1-2 dose levels). Based on the obtained clinical study data and the participants' benefit/risk assessments, the SMC may consider initiating some or all of the following cohorts and may terminate enrollment for certain cohorts early based on clinical study data after initiation: Cohort 1: Extensive-stage small cell lung cancer (ES-SCLC) after treatment failure of systemic standard of care; Cohort 2: Advanced/unresectable or metastatic HR+ HER2- breast carcinoma Cohort 3: Advanced/unresectable or metastatic castration-resistant prostate cancer (mCRPC) after treatment failure of systemic standard of care. Participants with prostate cancer whose disease is limited to metastases to bone will comprise no more than 20% of the enrolled population; Cohort 4: Advanced/unresectable or metastatic ovarian carcinoma

    Drug: SYS6043

Interventions

  • Administered by intravenous injection

06

What researchers measure

Primary outcomes

  1. Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a).

    Assessment of the MTD and/or RP2D (recommended Phase II dose).

    Time frame: An average of 1 year.

  2. Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities (DLTs) [Safety and Tolerability] of SYS6043 during the study (Phase 1a)

    Number of participants with dose-limiting toxicities (DLTs) as assessed by NCI CTCAE v5.0

    Time frame: An average 1 year

Secondary outcomes

  1. SYS6043 Pharmacokinetic

    SYS6043 Pharmacokinetic: Peak Plasma Concentration (Cmax)

    Time frame: An average 1 year

  2. SYS6043 Pharmacokinetic

    SYS6043 Pharmacokinetic: Area under the plasma concentration versus time curve (AUC)

    Time frame: An average 1 year

  3. SYS6043 Pharmacokinetic

    SYS6043 Pharmacokinetic: Elimination half-life (t1/2)

    Time frame: An average 1 year

  4. SYS6043 Pharmacokinetic

    SYS6043 Pharmacokinetic: Clearance (CL)

    Time frame: An average 1 year

  5. Objective response rate (ORR)

    Objective response rate (ORR). ORR is defined as the proportion of patients in whom a complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors is observed as best overall response.

    Time frame: An average 1 year

  6. SYS6043 Immunogenicity

    SYS6043 Immunogenicity: Number of participants with anti-drug-antibody (ADA).

    Time frame: An average 1 year

  7. B7-H3 protein expression levels

    B7-H3 protein expression levels

    Time frame: An average 1 year

07

Study locations

5 of 5 sites recruiting
  • BRCR Global
    Plantation, Florida 33322, United States
    Recruiting
    • Dr Sawhney, Principal Investigator · Contact561-447-0614
    • Dr Sawhney · Principal investigator
  • Florida Clinical Trials Group
    Plantation, Florida 33322, United States
    Recruiting
    • Dr Amin, Principal Investigator · Contact772-297-3057
    • Dr Amin · Principal investigator
  • NEXT Oncology Austin
    Austin, Texas 78758, United States
    Recruiting
    • Dr Sahota, Principal Investigator · Contact210-580-9500
    • Dr Sahota · Principal investigator
  • NEXT Oncology San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Dr Sommerhaulder, Principal Investigator · Contact210-580-9500
    • Dr Sommerhalder · Principal investigator
  • NEXT Oncology Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Dr Salkeni, Principal Investigator · Contact210-580-9500
    • Dr Salkeni · Principal investigator
08

References and documents

Publications

  • Diagnosis And Treatment Guidelines For Colorectal Cancer Working Group CSOCOC. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res. 2019 Feb;31(1):117-134. doi: 10.21147/j.issn.1000-9604.2019.01.07. No abstract available. PubMed 30996570 ↗
  • Chengyu Yan et al., 2023.Research Progress in Immunotherapy of Esophageal Cancer. Advances in Clinical Medicine; 13(5): 8107-8115.
  • Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Dec;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058. PubMed 34902832 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2029, 45 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 45 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 20, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Apr 2030
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07424547
Lead sponsor
Conjupro Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Mar 3, 2026
Primary completion
Dec 2029 (estimated)
Completion
Apr 2030 (estimated)
Last update
Apr 7, 2026

Study contacts

Director, Clinical Operations
Contact
clinicaltrials.gov@cspcus.com
609-356-0210
Regulatory Operations Manager
Contact
clinicaltrials.gov@cspcus.com
609-356-0210

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043

Start the discussion